GlaxoSmithkline Pharmaceuticals rose 0.12% to Rs 3,017 at 14:16 IST on BSE after the company declared result for the Q4 and full year ended 31 December 2013 during trading hours today, 18 February 2014.
Meanwhile, the S&P BSE Sensex was up 174.17 points or 0.85% at 20,638.23
On BSE, so far 10,815 shares were traded in the counter as against average daily volume of 7,055 shares in the past two weeks.
The stock gained as much as 0.25% at the day's high of Rs 3,021 so far during the day, also its record high. The stock was almost unchanged at the day's low of Rs 3,013.50 so far during the day. The stock had hit a 52-week low of Rs 2,076.05 on 25 February 2013.
The stock had outperformed the market over the past one month till 17 February 2014, rising 1.22% compared with the Sensex's 2.85% fall. The scrip had also outperformed the market in past one quarter, gaining 25.01% as against Sensex's 0.32% rise.
The large-cap company has equity capital of Rs 84.70 crore. Face value per share is Rs 10.
More From This Section
GlaxoSmithkline Pharmaceuticals' net profit fell 15.61% to Rs 116.88 crore on 2.74% decline in total income to Rs 685.04 in Q4 December 2013 over Q4 December 2012.
On a consolidated basis, GlaxoSmithkline Pharmaceuticals' net profit fell 14.27% to Rs 481.67 crore on 3.01% decline in total income to Rs 2739.64 in the year ended 31 December 2013 over the year ended 31 December 2012.
GlaxoSmithKline Pharmaceuticals board of directors of the company at its meeting held today, 18 February 2014, recommended the payment of a dividend of Rs 50 per share for the year ended 31 December 2013.
Meanwhile, the Britain-based GlaxoSmithKline Plc's voluntary open offer to the shareholders of its Indian subsidiary GlaxoSmithKline Pharmaceuticals started today, 18 February 2014. The offer will end on 5 March 2014. The global healthcare major plans to invest Rs 6390 crore to raise its stake in its Indian subsidiary to 75% from the existing 50.67%.
GlaxoSmithkline Pharmaceuticals is engaged in the business of manufacturing, distributing and trading in pharmaceuticals. The company's product portfolio includes prescription medicines and vaccines. Its prescription medicines range across therapeutic areas such as anti-infectives, dermatology, gynaecology, diabetes, oncology, cardiovascular diseases and respiratory diseases.
Powered by Capital Market - Live News